Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Scope, Share Analysis And Growth 2025

Focused on real-world business use, this report highlights what’s changing in the hypertrophic cardiomyopathy (hcm) therapeutics market and what companies should prepare for next.

What Is The Projected Market Size & Growth Rate Of The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market?
The hypertrophic cardiomyopathy (hcm) therapeutics market size has grown marginally in recent years. It will grow from $1.34 billion in 2024 to $1.37 billion in 2025 at a compound annual growth rate (CAGR) of 1.5%. The growth in the historic period can be attributed to diagnostic advancements, increased disease awareness, drug development and approvals, rising healthcare expenditure, government initiatives and funding.

The hypertrophic cardiomyopathy (hcm) therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.56 billion in 2029 at a compound annual growth rate (CAGR) of 3.4%. The growth in the forecast period can be attributed to genetic research and personalized medicine, emerging therapeutic modalities, collaborative research initiatives, patient-centric healthcare models, local health initiatives. Major trends in the forecast period include advancements in targeted therapies, personalized medicine and genetic testing, drug pipeline expansion, collaborations and partnerships, patient-centric approaches.

Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9914&type=smp

What Is The Crucial Factor Driving The Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market?
The increasing incidence of cardiovascular diseases (CVD) is expected to propel the growth of the hypertrophic cardiomyopathy (HCM) therapeutics market. Cardiovascular disease (CVD) is a condition that affects the heart or blood vessels. Cardiovascular diseases include heart irregularities such as atrial fibrillation, ventricular fibrillation, and atrioventricular block that require long-term monitoring. The primary need for therapeutics treatment for hypertrophic cardiomyopathy aims to alleviate symptoms and avoid sudden cardiac death in high-risk patients. For instance, according to the October 2022 report of the Center for Disease Control and Prevention (CDCP), a US-based national public health agency, in the United States, one person dies from cardiovascular disease every 36 seconds, and CVD is responsible for nearly 836,546 deaths in the United States alone in 2021. Therefore, the increasing incidence of cardiovascular diseases (CVD) drives the hypertrophic cardiomyopathy (HCM) therapeutics market.

Segment Covered In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report
The hypertrophic cardiomyopathy (hcm) therapeuticsmarket covered in this report is segmented –

1) By Drug Type: Antiarrhythmic Agents; Anticoagulants; Beta Adrenergic Blocking Agents; Calcium Channel Blockers; Other Drug Types
2) By Device Type: Defibrillators; Pacemakers; Other Device Types
3) By End User: Hospitals; Clinics

Subsegments:
1) By Antiarrhythmic Agents: Class I Agents; Class II Agents; Class III Agents; Class IV Agents
2) By Anticoagulants: Vitamin K Antagonists; Direct Oral Anticoagulants (DOACs); Low Molecular Weight Heparins (LMWH)
3) By Beta Adrenergic Blocking Agents: Non-Selective Beta Blockers; Selective Beta Blockers
4) By Calcium Channel Blockers: Dihydropyridines; Non-Dihydropyridines
5) By Other Drug Types: Myosin Inhibitors; Antimetabolites; Other Novel Agents

Key Trends Driving Growth In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market
Product innovations are the key trend gaining popularity in the hypertrophic cardiomyopathy (HCM) therapeutics market. Major companies operating in the cardiomyopathy therapeutics sector are focused on developing new innovative products to strengthen their position in the market. For instance, in April 2022, Bristol Myers Squibb, a US-based biopharmaceutical company, launched Camzyos (mavacamten), an oral small-molecule cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of heart diastolic dysfunction. Camzyos (mavacamten) was approved by the US Food and Drug Administration (FDA) for the treatment of adults with symptomatic class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms. Camzyos is the first and only FDA-approved allosteric and reversible inhibitor of cardiac myosin that targets the underlying pathophysiology of obstructive HCM. Camzyos controls the number of myosin heads that can enter ‘on actin’ (power-generating) states.

Key Player In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market
Major companies operating in the hypertrophic cardiomyopathy (HCM) therapeutics market include Merck & Co. Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc, Gilead Sciences Inc., Bayer AG, Correvio Pharma Corp., Advanz Pharma Corp., Lupin Limited, Boston Scientific Corporation, Bristol-Myers Squibb Company, Johnson & Johnson, Medtronic plc, Cardiome Pharma Corp., Cytokinetics Inc., Daiichi Sankyo Company Limited, GlaxoSmithKline plc., HUYA Bioscience International LLC, Ionis Pharmaceuticals Inc., Kowa Company Ltd., Luitpold Pharmaceuticals Inc., Menarini Group, Mitsubishi Tanabe Pharma Corporation, Nippon Shinyaku Co. Ltd., Otsuka Holdings Co. Ltd., Servier Laboratories

View the full hypertrophic cardiomyopathy (hcm) therapeutics market report here:
https://www.thebusinessresearchcompany.com/report/hypertrophic-cardiomyopathy-hcm-therapeutics-global-market-report

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market - Regional Insights:
North America was the largest region in the hypertrophic cardiomyopathy (HCM) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the hypertrophic cardiomyopathy (HCM) therapeutics market report during the forecast period. The regions covered in the hypertrophic cardiomyopathy (HCM) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company